Prot #PAC326: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Project: Research project

Project Details

StatusFinished
Effective start/end date1/6/15 → 1/6/18

Funding

  • CTI BioPharma Corp. (Prot #PAC326)